Skip to Main Content

Author Details

Markus Riester
Novartis Institutes for BioMedical Research
2005
42
26
PMIDPaper TitleJournal TitlePublished Year
37603596Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance.Cancer Res2023
37603596Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance.Cancer Res2023
35655320A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.J Exp Clin Cancer Res2022
35655320A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.J Exp Clin Cancer Res2022
32282230Reliable Analysis of Clinical Tumor-Only Whole-Exome Sequencing Data.JCO Clin Cancer Inform2020
32282230Reliable Analysis of Clinical Tumor-Only Whole-Exome Sequencing Data.JCO Clin Cancer Inform2020
32747365Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma.Cancer Res2020
33298926TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts.Nat Commun2020
33298926TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts.Nat Commun2020
32747365Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma.Cancer Res2020
30643118Author Correction: Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features.Nat Commun2019
30643118Author Correction: Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features.Nat Commun2019
30667365Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials.Endocr Relat Cancer2019
30667365Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials.Endocr Relat Cancer2019
29045536The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation.Ann Oncol2018
29045536The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation.Ann Oncol2018
30327465Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features.Nat Commun2018
30275569Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.Nat Med2018
29376144Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.JCO Precis Oncol2018
30275569Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.Nat Med2018
30327465Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features.Nat Commun2018
29376144Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.JCO Precis Oncol2018
29092936Software for the Integration of Multiomics Experiments in Bioconductor.Cancer Res2017
28333954Distance in cancer gene expression from stem cells predicts patient survival.PLoS One2017
29092936Software for the Integration of Multiomics Experiments in Bioconductor.Cancer Res2017
28126923Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells.Nucleic Acids Res2017
28333954Distance in cancer gene expression from stem cells predicts patient survival.PLoS One2017
28126923Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells.Nucleic Acids Res2017
27008014Meta-Analysis in Gene Expression Studies.Methods Mol Biol2016
27148582Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus.Cold Spring Harb Mol Case Stud2016
27381624The Doppelgänger Effect: Hidden Duplicates in Databases of Transcriptome Profiles.J Natl Cancer Inst2016
27008014Meta-Analysis in Gene Expression Studies.Methods Mol Biol2016
27091708Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.J Clin Oncol2016
27999612PureCN: copy number calling and SNV classification using targeted short read sequencing.Source Code Biol Med2016
27999612PureCN: copy number calling and SNV classification using targeted short read sequencing.Source Code Biol Med2016
27148582Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus.Cold Spring Harb Mol Case Stud2016
27381624The Doppelgänger Effect: Hidden Duplicates in Databases of Transcriptome Profiles.J Natl Cancer Inst2016
27091708Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.J Clin Oncol2016
25572172JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.Cancer Discov2015
25886454DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors.BMC Cancer2015
25572172JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.Cancer Discov2015
25720673HER2 as a target in invasive urothelial carcinoma.Cancer Med2015
26039708Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors.PLoS One2015
26379039An Evolutionary Approach for Identifying Driver Mutations in Colorectal Cancer.PLoS Comput Biol2015
26379039An Evolutionary Approach for Identifying Driver Mutations in Colorectal Cancer.PLoS Comput Biol2015
26039708Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors.PLoS One2015
25886454DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors.BMC Cancer2015
25720673HER2 as a target in invasive urothelial carcinoma.Cancer Med2015
24486590Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma.Clin Cancer Res2014
25269490Molecular subtypes of high-grade serous ovarian cancer: the holy grail?J Natl Cancer Inst2014
  • 1 - 50 of 84

Recommended Authors

Arshi Arora
Memorial Sloan Kettering Cancer Center
Career Start Year 2011
Number of shared co-authors 3
Chen Wang
Center for Individualized Medicine, Mayo Clinic
Career Start Year 2011
Number of shared co-authors 2
Yuan Yuan
The University of Texas MD Anderson Cancer Center
Career Start Year 2011
Number of shared co-authors 2
Gunes Gundem
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 1
Darragh G McArt
Queen's University Belfast
Career Start Year 2009
Number of shared co-authors 0
Ken Chen
University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 7
Siyuan Zheng
Greehey Children's Cancer Research Institute
Career Start Year 2007
Number of shared co-authors 5
David C Wedge
Manchester Cancer Research Centre, University of Manchester
Career Start Year 2006
Number of shared co-authors 3
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 2
Matti Nykter
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 2006
Number of shared co-authors 1
Joshy George
Peter MacCallum Cancer Centre
Career Start Year 2005
Number of shared co-authors 7
Christina Curtis
Stanford University School of Medicine
Career Start Year 2004
Number of shared co-authors 4
Katherine A Hoadley
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Career Start Year 2004
Number of shared co-authors 7
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 14
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 8
Olivier Harismendy
University of California
Career Start Year 2003
Number of shared co-authors 1
Sohrab P Shah
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 0
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 3
Amy G Robertson
Present address: Dxige Research Inc.
Career Start Year 2003
Number of shared co-authors 6
Leslie Cope
Johns Hopkins University School of Medicine
Career Start Year 2003
Number of shared co-authors 8
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 7
Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Career Start Year 2000
Number of shared co-authors 2
Andrea Sboner
Institute for Computational Biomedicine
Career Start Year 2000
Number of shared co-authors 11
Gad Getz
Broad Institute of the Massachusetts Institute of Technology and Harvard
Career Start Year 2000
Number of shared co-authors 22
Li Ding
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 1997
Number of shared co-authors 5
Benedikt Brors
German Cancer Research Center (DKFZ)
Career Start Year 1997
Number of shared co-authors 6
Ole Christian Lingj??rde
University of Oslo
Career Start Year 1997
Number of shared co-authors 1
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 4
Adam B Olshen
12224University of California san francisco
Career Start Year 1993
Number of shared co-authors 1
Paul C Boutros
University of California los angeles
Career Start Year 1970
Number of shared co-authors 9

Collaborators

Levi Waldron
City University of New York School of Public Health
Co-authored papers 10
Giovanni Parmigiani
Dana Farber Cancer Institute.
Co-authored papers 6
Michael Morrissey
Co-authored papers 6
Michael J Birrer
Co-authored papers 6
Toni K Choueiri
Dana-Farber Cancer Institute
Co-authored papers 4
Rebecca J Leary
Co-authored papers 4
Curtis Huttenhower
Broad Institute of MIT and Harvard
Co-authored papers 4
Massimo Loda
Weill Medical College of Cornell University
Co-authored papers 4
Marcel Ramos
Graduate School of Public Health and Health Policy, City University of New York
Co-authored papers 4
David M Berman
Queen's University
Co-authored papers 3
Wendy Winckler
Co-authored papers 3
Aedin C Culhane
Dana-Farber Cancer Institute & Harvard School of Public Health
Co-authored papers 3
Benjamin Haibe-Kains
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 3
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Martin Morgan
Roswell Park Comprehensive Cancer Center
Co-authored papers 3
Jordi Barretina
Co-authored papers 2
Peter F Stadler
Co-authored papers 2
Subhajyoti De
Co-authored papers 2
Rong Fan
Institute of Pathogens and Vectors, Dali University
Co-authored papers 2
Chibuzor Nkwodimmah
University of Ibadan
Co-authored papers 2
Catarina D Campbell
Co-authored papers 2
Scott Mahan
Co-authored papers 2
Sehyun Oh
Graduate School of Public Health and Health Policy, City University of New York
Co-authored papers 2
Lucas Schiffer
Boston University
Co-authored papers 2
A Jason Grundstad
Co-authored papers 2
Peter Van Loo
The Francis Crick Institute
Co-authored papers 2
Kevin P White
Co-authored papers 2
Ludwig Geistlinger
Center for Computational Biomedicine, Harvard Medical School
Co-authored papers 2
Jiebiao Wang
Co-authored papers 2
Barbara L Weber
Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania
Co-authored papers 2
Release 1.2